Article info

Download PDFPDF

Editorial
Anifrolumab: the new frontier in the treatment of genetic interferonopathies

Authors

  • Marie-Louise Frémond Department of Paediatric Hematology-Immunology and Rheumatology, Centre de Référence des Rhumatismes inflammatoires, maladies Auto-immunes et Interféronopathies Systémiques de l'Enfant RAISE, Necker-Enfants Malades Hospital, AP-HP, Paris, FranceLaboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France PubMed articlesGoogle scholar articles
  • Clémence David Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France PubMed articlesGoogle scholar articles
  • Christophe Richez Department of Rheumatology, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpital Pellegrin, Bordeaux, FranceImmunoConcEpT, CNRS UMR 5164, University Bordeaux, Bordeaux, France PubMed articlesGoogle scholar articles
  1. Correspondence to Pr Marie-Louise Frémond; marie-louise.fremond{at}aphp.fr; Pr Christophe Richez; christophe.richez{at}chu-bordeaux.fr
View Full Text

Citation

Frémond M, David C, Richez C
Anifrolumab: the new frontier in the treatment of genetic interferonopathies

Publication history

  • Received July 17, 2024
  • Accepted August 16, 2024
  • First published September 23, 2024.
Online issue publication 
September 23, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.